2013
DOI: 10.5607/en.2013.22.2.84
|View full text |Cite
|
Sign up to set email alerts
|

An Update of Animal Models of Alzheimer Disease with a Reevaluation of Plaque Depositions

Abstract: Animal models of Alzheimer disease (AD) are used to study the mechanisms underlying AD pathogenesis, genetic interactions with genes of interest, and environmental risk factors that cause sporadic AD as well as to test the therapeutic effects of AD drug-candidates on neuropathology and cognitive function. To attain a comparative view on the AD models developed, representative AD lines were selected and summarized with respect to transgenic constructs and AD-related pathology. In addition, age-dependent plaque … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
60
0
1

Year Published

2015
2015
2020
2020

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 84 publications
(63 citation statements)
references
References 85 publications
2
60
0
1
Order By: Relevance
“…It was also projected the genetic cause of Alzheimer disease (AD) is understood for less than 1% gene mutations (APP, PS1, PS2) in early onset FAD or 20% (APOE4 allele) in late onset FAD cases, respectively [31]. For the remainder of AD sufferers, multiple genetic and environmental factors probably play a role in contributing to disease onset, severity and progression due to promotion of amyloid-beta peptide (Aβ42/40) generation following proceeding of APP cleavage due to secretase activation [3234]. To date, there is no cure for AD and therapeutic measures are being actively explored through small molecule likely inhibitors to three isoform of secretases and/or neutralization of amyloid-beta peptide (Aβ42/40) toxicity using biologicals, small molecules, and immunotherapy in the pharmacological active natural compounds.…”
Section: Discussionmentioning
confidence: 99%
“…It was also projected the genetic cause of Alzheimer disease (AD) is understood for less than 1% gene mutations (APP, PS1, PS2) in early onset FAD or 20% (APOE4 allele) in late onset FAD cases, respectively [31]. For the remainder of AD sufferers, multiple genetic and environmental factors probably play a role in contributing to disease onset, severity and progression due to promotion of amyloid-beta peptide (Aβ42/40) generation following proceeding of APP cleavage due to secretase activation [3234]. To date, there is no cure for AD and therapeutic measures are being actively explored through small molecule likely inhibitors to three isoform of secretases and/or neutralization of amyloid-beta peptide (Aβ42/40) toxicity using biologicals, small molecules, and immunotherapy in the pharmacological active natural compounds.…”
Section: Discussionmentioning
confidence: 99%
“…In previous studies, it has been suggested that Tg2576 mice exhibited deficits in tests of spatial memory after 6 months of age (Hsiao, et al, 1996; King, et al, 1999; Westerman, et al, 2002), when β-amyloid plaques becomes prominent (Hsiao, et al, 1996; Lee and Han, 2013). Our results suggest that when a task of spatial memory is used that is dependent on the EC, such as OP, impairments can be detected earlier.…”
Section: Discussionmentioning
confidence: 99%
“…To gain insight into these questions, we used the Tg2576 mouse model of AD neuropathology. The Tg2576 mouse uses the hamster prion promoter to overexpress human amyloid precursor protein (hAPP) 695 with the mutation of a Swedish family with AD (K670N/M671L), and progressive Aβ pathology occurs after 6 months of age (Hsiao, et al, 1996; Irizarry, et al, 1997; Kawarabayashi, et al, 2001; Lee and Han, 2013; Westerman, et al, 2002). …”
Section: Introductionmentioning
confidence: 99%
“…Chronic stress in adulthood e.g. elevates Aβ 40 and Aβ 42 brain levels, accelerates amyloid plaque formation, increases tauopathy and neuronal atrophy, and impairs learning and memory in various mouse models [1113]. …”
Section: Introductionmentioning
confidence: 99%